Fintel reports that on March 14, 2025, Wedbush downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from Outperform ...

Fintel reports that on March 14, 2025, Citizens Capital Markets downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) ...

Sutro Biopharma, a Bay Area oncology biotech company, is laying off around half its staff, switching up its leadership team ...

BofA downgraded Sutro Biopharma (STRO) to Underperform from Buy with a price target of $1, down from $11, following the company’s announcement ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a hold rating to a sell rating in a research report released on Thursday morning. A number of other equities research ...

Thermo Fisher is among the industry's best when it comes to cost control. As near-term spending is constrained, the company's margins show exceptional resilience. As of fiscal year-end 2024, Thermo ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition - - Cash, cash equivalents ...

Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner - - Three INDs for wholly ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

Juliette Han is the COO of Cambrian Biopharma, which aims to shape society through equitable access to healthful aging, ...